CAMP4 Therapeutics Corporation Comprehensive Income
CAMP4 Therapeutics Corporation (CAMP) reported Comprehensive Income of -$33.53 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:ComprehensiveIncomeNetOfTax · last filed 2026-08-13
- CAMP4 Therapeutics Corporation comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-06-30 was -$33.53M.
- CAMP4 Therapeutics Corporation comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-03-31 was -$18.33M.
- CAMP4 Therapeutics Corporation comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-12-31 was -$40.28M.
- CAMP4 Therapeutics Corporation comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-09-30 was -$15.10M.
- CAMP4 Therapeutics Corporation comprehensive income (loss), net of tax, attributable to parent for fiscal 2025 was -$80.40M.
- CAMP4 Therapeutics Corporation comprehensive income (loss), net of tax, attributable to parent for fiscal 2024 was -$51.79M.
- CAMP4 Therapeutics Corporation comprehensive income (loss), net of tax, attributable to parent for fiscal 2023 was -$49.29M.
| Period end | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$33.53M 10-Q · filed 2026-08-13 | -$51.86M 10-Q · filed 2026-08-13 | -$92.14M derived: sum of 3 quarters · filed 2026-08-13 | -$107.24M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | -$18.33M 10-Q · filed 2026-05-07 | -$58.62M derived: sum of 2 quarters · filed 2026-05-07 | -$73.71M derived: sum of 3 quarters · filed 2026-05-07 | -$86.30M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | -$40.28M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$55.38M derived: sum of 2 quarters · filed 2026-03-05 | -$67.97M derived: sum of 3 quarters · filed 2026-08-13 | -$80.40M 10-K · filed 2026-03-05 |
| 2025-09-30 | -$15.10M 10-Q · filed 2025-11-06 | -$27.69M derived: sum of 2 quarters · filed 2026-08-13 | -$40.12M 10-Q · filed 2025-11-06 | -$53.40M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | -$12.59M 10-Q · filed 2026-08-13 | -$25.02M 10-Q · filed 2026-08-13 | -$38.30M derived: sum of 3 quarters · filed 2026-08-13 | -$51.78M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | -$12.43M 10-Q · filed 2026-05-07 | -$25.71M derived: sum of 2 quarters · filed 2026-05-07 | -$39.20M derived: sum of 3 quarters · filed 2026-05-07 | -$51.77M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$13.28M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$26.76M derived: sum of 2 quarters · filed 2026-03-05 | -$39.34M derived: sum of 3 quarters · filed 2026-03-05 | -$51.79M 10-K · filed 2026-03-05 |
| 2024-09-30 | -$13.48M 10-Q · filed 2025-11-06 | -$26.06M derived: sum of 2 quarters · filed 2025-11-06 | -$38.51M 10-Q · filed 2025-11-06 | -$51.50M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | -$12.58M 10-Q · filed 2025-08-14 | -$25.03M 10-Q · filed 2025-08-14 | -$38.02M derived: sum of 3 quarters · filed 2025-08-14 | -$49.71M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | -$12.45M 10-Q · filed 2025-05-13 | -$25.44M derived: sum of 2 quarters · filed 2025-05-13 | -$37.14M derived: sum of 3 quarters · filed 2025-05-13 | |
| 2023-12-31 | -$12.99M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | -$24.69M derived: sum of 2 quarters · filed 2025-03-27 | -$49.29M 10-K · filed 2025-03-27 | |
| 2023-09-30 | -$11.70M 10-Q · filed 2024-11-21 | -$36.30M 10-Q · filed 2024-11-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |